title: Pheochromocytoma: the expanding genetic differential diagnosis.
abstract: Pheochromocytomas and paragangliomas are tumors of the autonomic nervous system; pheochromocytomas are tumors of the adrenal medulla, and paragangliomas are extra-adrenal tumors arising from either the sympathetic nervous system or parasympathetic ganglia. It has previously been estimated that approximately 10%-15% of pheochromocytomas are due to hereditary causes. However, our increased understanding of the three hereditary syndromes (neurofibromatosis 1, multiple endocrine neoplasia type 2, and von Hippel-Lindau syndrome) in which pheochromocytoma is found and the recent discovery that mutations in genes in the succinate dehydrogenase family (SDHB and SDHD) predispose to pheochromocytoma have necessitated a re-evaluation of the genetic basis of pheochromocytoma. These studies indicate that the frequency of germline mutations associated with isolated pheochromocytoma is higher than previously estimated, with both hospital-based series and a large population-based series indicating that the frequency of germline mutations in RET, VHL, SDHB, and SDHD taken together approximates 20%. In all patients with pheochromocytoma, including those with known hereditary syndrome or a positive family history, the frequency of germline mutations in these four genes together approaches 30%. Given the frequency of germline mutations, consideration should be given to genetic counseling for all patients with pheochromocytoma and is particularly important for individuals with a positive family history, multifocal disease, or a diagnosis before age 50. Identification of patients with hereditary pheochromocytoma is important because it can guide medical management in mutation-positive patients and their families. This review provides an overview of the known genetic syndromes that are commonly associated with pheochromocytoma, examines recent data on the association of germline mutations in the succinate dehydrogenase gene family with pheochromocytoma, and suggests guidelines for the genetic evaluation of pheochromocytoma patients.
authors.affiliation: Division of Medical Genetics, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia 19104, USA.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Bryant
authors.forename: Jennifer
authors.initials: J
authors.lastname: Farmer
authors.forename: Lisa J
authors.initials: LJ
authors.lastname: Kessler
authors.forename: Raymond R
authors.initials: RR
authors.lastname: Townsend
authors.forename: Katherine L
authors.initials: KL
authors.lastname: Nathanson
mesh_terms: D000310:Adrenal Gland Neoplasms / Q000175:diagnosis* / Q000201:enzymology / Q000235:genetics*; D014408:Biomarkers, Tumor; D003937:Diagnosis, Differential; D005819:Genetic Markers; D018095:Germ-Line Mutation; D006801:Humans; D018813:Multiple Endocrine Neoplasia Type 2a / Q000175:diagnosis / Q000235:genetics; D009456:Neurofibromatosis 1 / Q000175:diagnosis / Q000235:genetics; D010236:Paraganglioma, Extra-Adrenal / Q000175:diagnosis / Q000235:genetics; D010257:Paraneoplastic Syndromes / Q000175:diagnosis / Q000235:genetics; D010673:Pheochromocytoma / Q000175:diagnosis* / Q000201:enzymology / Q000235:genetics*; D013385:Succinate Dehydrogenase / Q000235:genetics*; D006623:von Hippel-Lindau Disease / Q000175:diagnosis / Q000235:genetics
chemical_list: D014408:Biomarkers, Tumor; D005819:Genetic Markers; D013385:Succinate Dehydrogenase